Compare Citius Pharmaceuticals Inc (CTXR) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Palo Alto Networks Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while Palo Alto Networks Inc trades at $385.77 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 15632.2× Citius Pharmaceuticals Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | PANW | |
|---|---|---|
Market Cap | $20.01M | $312.80B |
Sector | Health | Technology |
52-Week High | $1.82 | $385.04 |
52-Week Low | $0.48 | $141.67 |
Enterprise Value | $16.23M | $311.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Palo Alto Networks (PANW) trades at $384.29, down 0.19% on the day, with a bullish technical signal supported by moving averages and strong institutional sentiment. Revenue grew to $9.22B in FY2025, with net income of $1.13B, though valuation ratios like P/E of 333.74 and P/S of 26.64 appear elevated. Recent news highlights AI-driven cybersecurity demand and a China regulatory review, while the company beat EPS estimates in three consecutive quarters.
Outlook remains positive due to robust AI security growth and analyst consensus, but risks include high valuation, integration costs from acquisitions, and geopolitical scrutiny. The stock's proximity to its 52-week high suggests cautious optimism, with upside potential tied to execution on AI initiatives and cybersecurity spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
